Investigation of injectable drug utilization in primary care: A focus on different age groups in pediatric population

N Akici1, V Aydin2, B Donertas3

  • 1Department of Pediatrics, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.

Insights

Pediatric injectable drug use in primary care is often inappropriate, with antibiotics and cephalosporins frequently overprescribed, especially for younger children. This highlights a need for rational pharmacotherapy in pediatric populations.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Public Health

Background:

  • Injectable drug suitability varies by age, particularly in children, necessitating an understanding of usage patterns for rational pharmacotherapy.
  • Pediatric injectable drug utilization in primary care requires investigation to ensure appropriate treatment.

Purpose of the Study:

  • To investigate pediatric injectable drug utilization in primary care settings.
  • To analyze drug usage patterns across different pediatric age groups: infants, children, and adolescents.

Main Methods:

  • A simple sampling method was used to select 100 prescriptions containing injectable drugs per month over a year from 32 Turkish provinces (total n=38,400).
  • Injectable drugs prescribed to children (<18 years) were analyzed.
  • Drug utilization patterns were compared among infants, children, and adolescents.

Main Results:

  • 5446 pediatric patients (14.2%) were identified, with a mean age of 7.4 years.
  • Respiratory system indications, primarily infections (96.3%), were most common (65.4%).
  • Antibiotics were the most prescribed injectable drugs across all age groups (61.5%-79.9%), predominantly penicillins and cephalosporins. Third-generation cephalosporins were more common in infants, while penicillins dominated in children and adolescents. Analgesics and insulin were more frequent in adolescents. Costs increased with age.

Conclusions:

  • Primary care physicians frequently use injectable antibiotics, particularly third-generation cephalosporins, in pediatric patients, especially younger children.
  • This pattern suggests potentially inappropriate use of injectable drugs for managing pediatric conditions in primary care.
  • The findings underscore the need for improved guidelines and rational pharmacotherapy in pediatric injectable drug prescription.
Abstract

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
177
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
133
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
194
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
164